The role of stem cell transplantation in multiple myeloma

Blood Reviews

Volumn 16, Issue 4, 2002, Pages 245-253

  Harousseau, Jean Luc ^a   Attal, Michel ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Allogeneic bone marrow transplantation; Autologous stem cell transplantation; Multiple myeloma

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; MELPHALAN; PREDNISONE; VINCRISTINE;

ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHROMOSOME 13; CHROMOSOME ABERRATION; DOSE RESPONSE; DRUG FATALITY; DRUG INDUCED DISEASE; GRAFT VERSUS HOST REACTION; HLA SYSTEM; HUMAN; KIDNEY FAILURE; LYMPHOID CELL; MAINTENANCE THERAPY; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NEUTROPENIA; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; WHOLE BODY RADIATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METHODOLOGY; MORTALITY; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTIPLE MYELOMA; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0036883498     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(02)00043-7     Document Type: Review

References (61)

1. Bataille R, Harousseau JL. Multiple myeloma (Review Article). N Engl J Med 1997; 36: 1657-1664.
2. Harousseau JL, Attal M. The role of autologous hematopoietic stem cell transplantaton in multiplemyeloma. Semin Hematol 1997; 34(Suppl. 1): 61-66.
3. Blade J, San Miguel JF, Montserrat F et al. Survival of multiple myeloma patients who are potent al candidates for early high-dose therapy intensifcation/autotransplantation and who were conventionally treated. J Clin Oncol 1996; 14: 2167-2173.
4. Barlogie B, Jagannath S, Vesole D et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789-793.
5. Lenhoff S, Hjorth M, Holmberg E et al. Impact of survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma. Blood 2000; 95: 7-11.
6. Palumbo A, Triolo S, Argentin C. Dose intensive melphalan with stem-cell support is superior to standard treatment in elderly myeloma patients. Blood 1999; 94: 1248-1253.
7. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-97.
8. Fermand JP, Ravaud P, Katsahian S et al. High dose therapy and autologous blood stem cell transplantation versus conventional treatment in multiple myeloma: Results of a randomized trial in 190 patients 55-65 years of age. Blood 1999; 94(Suppl. 1): 396a (Abstract).
9. Blade J, Sureda A, Ribera JM et al. High-dose therapy autotransplantation/intensification vs continued conventional chemotherapy in multiple myeloma in patients responding to initial treatment chemotherapy. Results of a prospective randomized trial from the Spanish Cooperative Group PETHEMA. Blood 2001; 98: 815a (Abstract).
10. 2) vs oral melphalan/ prednisone: An interim analysis. Blood 2001; 98: 849a (Abstract).
11. Fermand JP, Ravaud P, Chevret S et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or resume treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998; 92: 3131-3136.
12. Barlogie B, Alexanian R, Dicke K et al. High dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987; 70: 869-872.
13. Cunningham D, Paz-Ares L, Milan S et al. High dose Melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994; 12: 759-763.
14. Moreau P, Facon T, Attal M et al. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140mg/m2 as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma. Final analysis of the IFM 95-02 randomized trial. Blood 2002; 99: 731-735.
15. Goldschmidt H, Hegenbart U, Wallmeier M et al. High-dose therapy with peripheral blood progenitor cell transplantation in multiple myeloma. Ann Oncol 1997; 8: 243-246.
16. Bjorkstrand B, Svensson H, Goldschmidt H et al. 5489 Autotransplants in multiple myeloma: A registry from the EBMT. Blood 1999; 94(Suppl. 1): 714a (Abstract).
17. 2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant 1999; 23: 1000-1006.
18. Moreau P, Harousseau JL, Wijdenes J, Morineau N, Milpied N, Bataille R. A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose Melphalan induces high complete response rate in advanced multiple myeloma. Br J Haematol 2000; 109: 661-664.
19. Lahuerta JJ, Grande C, Blade J et al. Myeloablative treatments for multiple myeloma: Update of comparative study of different regimens used in patients from the Spanish Registry for Transplantation in Multiple Myeloma. Leuk Lymph 2002; 43: 67-74.
20. Harousseau JL, Milpied N, Laporte JP et al. Double intensive therapy in high-risk multiple myeloma. Blood 1992; 79: 2827-2833.
21. Vesole D, Barlogie B, Jagannath S et al. High-dose therapy for refractory multiple myeloma: Improved prognosis with better supportive care and double transplants. Blood 1994; 84: 950-956.
22. Weaver CH, Zhen B, Schwartzberg LS et al. Phase I-II evaluation of rapide sequence tandem high-dose melphalan with peripheral blood stem cell support in patients with multiple myeloma. Bone Marrow Transplant 1998; 22: 245-251.
23. Bjorkstrand B, Ljungman P, Bird JM, Samson D, Gahrton G. Double high-dose chemoradiotherapy with autologous stem cell transplantation can induce molecular remission in multiple myeloma. Bone Marrow Transplant 1995; 15: 367-371.
24. Vesole D, Tricot G, Jagannath S et al. Autotransplant in multiple myeloma: What have we learned?. Blood 1996; 88: 838-847.
25. Desikan R, Barlogie B, Sawyer J et al. Results of high dose therapy for 1000 patients with multiple myeloma: Durable complete remission and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95: 4008-4010.
26. Attal M, Harousseau JL, Facon T et al. Single versus double transplant in myeloma: A randomized trial of the IFM. In: Proceedings of the VIIIth International Myeloma Workshop, S15. 2001. p. 28 (Abstract).
27. Segeren CM, Sonneveld P, Van Der Holt P et al. Myeloablative treatment in following intensified chemotherapy untreated multiple myeloma: A prospective randomized Phase III. Blood 2001; 98: 815a.
28. Caro M, Tosi P, Zamagni E et al. The BOlogna 96 clinical trial of single versus double PBSC transplantation for previously untreated MM: results of an interim analysis. In: Proceedings of the VIIIth International Myeloma Workshop, S16. 2001. p. 29.
29. Fermand JP, Marolleau JP, Alberti C et al. Single versus tandem high dose therapy supported with autologous stem cell transplantation using unselected or CD34 enriched ABSC: preliminary results of a two by two designed randomized trial in 23 young patients with multiple myeloma. Blood 2001; 98: 815a (Abstract).
30. Schiller G, Vescio R, Freytes C et al. Transplantation of CD34+ peripheral blood progenitor cell after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 1995; 86: 390-397.
31. Lemoli RM, Fortuna A, Motta MR et al. Concomittant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: Positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells. Blood 1996; 87: 1625-1634.
32. Vescio RA, Schiller G, Stewart K et al. Multicenter Phase III trial to evaluate CD34+ selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood 1999; 93: 1858-1868.
33. Stewart AK, Vescio K, Schiller G et al. Purging of autologous peripheral blood stem cells using CD34 selection does not improve overall or progression free survival after high-dose therapy for multiple myelome: results of a multicenter randomized controlle trial. J Clin Oncol 2001; 198: 3771-3779.
34. Goldschmidt H, Bouko Y, Bourhis JH et al. CD34+ selected PBPCT results in an increased infective risk without prolongation of event free survival in newly diagnosed myeloma: A randomised study from the EBMT. Blood 2000; 96: 558a (Abstract).
35. Gazitt Y, Reading CC, Hoffman R et al. Purified CD34+ Linthy + stem cells do not contain clonal myeloma cells. Blood 1995; 86: 381-389.
36. Tricot G, Gazitt Y, Leemhuis S et al. Collection, tumor contamination and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma. Blood 1998; 91: 4489-4495.
37. Tricot G, Jagannath S, Vesole D et al. Peripheral blood stem cell transplants for multiple myeloma: Identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588-596.
38. Harousseau JL. Optimizing peripheral blood progenitor cell autologous transplantation in multiple myeloma. Haematologica 1999;84:548-553.
39. Facon T, Harousseau JL, Maloisel F et al. Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma: A randomized, controlled trial. Blood 1999; 94: 1218-1225.
40. Bjorkstrand B, Svensson H, Goldschmidt H et al. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: A retrospective registry study from the EBMT. Bone Marrow Transplant 2001; 27: 511-515.
41. Cunningham D, Powles R, Malpas J et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: Long term follow-up results. Br J Haematol 1998; 102:195-202.
42. Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 66-75.
43. Facon T, Avet-Loiseau H, Guillerm G et al. Chromosome 13 abnormalities identified by Fish analysis and serum β2 microglobulin produce powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97: 1566-1571.
44. Lahuerta JJ, Martinez-Lopez J, de la Serna J et al. Remission status defined by immunofixation vs electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 2000; 109: 438-446.
45. Davies FE, Forsyth PD, Rawstron AC et al. The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br J Haematol 2001; 112: 814-819.
46. Siegel DS, Desikan KR, Nehta J et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999; 93: 51-54.
47. Badros A, Barlogie B, Siegel E et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001; 114: 600-607.
48. Badros A, Barlogie B, Siegel E et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114: 822-829.
49. Tricot G, Alberts DS, Johnson C et al. Safety of autotransplants with high-dose melphalan in renal failure: A pharmacokinetic and toxicity study. Clin Cancer Res 1996; 2: 947-952.
50. Ballester B, Tummala R, Janssen WE et al. High dose therapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal failure. Bone Marrow Transplant 1997;20:653-656.
51. Tosi P, Zamagni E, Ronconi S et al. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. Crit Care Med 2002; 30: 753-756.
52. San Miguel J, Lahuerta JJ, Garcia-Sanz R et al. Are myeloma patients with renal failure candidate for autologous stem cell transplantation. Hematol J 2000; 1: 28-36.
53. Björkstrand B, Ljungman P, Svensson H et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996; 88: 4711-4718.
54. Corradini P, Voena C, Tarella C et al. Mollecular and clinical remissions in multiple myeloma: Role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999; 17: 208-215.
55. Gahrton G, Tura S, Ljungman P et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995;13:1312-1322.
56. Tricot G, Vesole DH, Jagannath S et al. Graft-versus myeloma effect: Proof of principle. Blood 1996; 87: 1196-1198.
57. Verdonck L, Lokhorst H, dekker A et al. Graft versus myeloma effect in two cases. Lancet 1996; 347: 800-801.
58. Gahrton G, Svensson H, Cavo M et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: A comparison between transplants performed 1983-1993 and 1994-1998 at European Group for Blood and Marrow Transplantation centers. Br J Haematol 2001; 113: 209-216.
59. Alyea E, Weller E, Schlossman R et al. T-cell depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus myeloma effect. Blood 2001; 98: 934-939.
60. Badros A, Barlogie B, Siegel E et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after non-myeloablative conditioning. J Clin Oncol 2002; 20: 1295-1303.
61. Maloney DG, Sahebi F, Stockerl-Goldstein KE et al. Combining and allogeneic graft-versus myeloma effect with high-dose autologous stem cell rescue in the treatment of multiple myeloma. Blood 2001; 98: 434a.